Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: Implications for cardiovascular risk

Gynecological Endocrinology

Volumn 20, Issue 3, 2005, Pages 176-182

  Heald, Adrian ^a,b   Kaushal, Kalpana ^a   Anderson, Simon ^a   Redpath, Mark ^a   Durrington, Paul N ^a   Selby, Peter L ^a   Gibson, Martin J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

Bone; Cardiovascular risk; Estrogen; Insulin like growth factor; Progestogen

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DESOGESTREL; ESTROGEN; GESTAGEN; NORETHISTERONE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C;

ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DESOGESTREL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROGESTINS; RISK FACTORS;

EID: 18844375867     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400027406     Document Type: Article

References (33)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestogen in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
2. Hulley S, Grady H, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestogen for secondary prevention of heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13.
3. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2004;291:1701-12.
5. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50.
6. Horsmann A, Gallagher JC, Simpson M, Nordin BEC. Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J 1977;ii:789-92.
7. Christiansen C, Riis BJ, Nilas L, Rødbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis. Lancet 1985;ii:800-1.
8. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytarak N, Robinson V, Henry D, O'Connell D, Cranney A. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39.
9. Janssen JAMJL, Stolk RP, Pols HAP, Grobbee DE, Lamberts SWJ. Serum total IGF-I, free IGF-I and IGFBP-1 levels in an elderly population. Arterioscler Thromb Vasc Biol 1998;18:277-82.
10. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, et al. Close relationship of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in 2 populations. Diabetologia 2001;44:333-9.
11. Cruickshank JK, Heald AH, Anderson SG, Cade JE, Sampayo J, Riste LK, Greenhalgh A, Taylor W, Fraser W, White A, et al. The epidemiology of the insulin-like growth factor system in 3 ethnic groups. Am J Epidemiol 2001;154:504-13.
12. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.
13. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
14. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
15. Mohan S, Baylink DJ. Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm Res 1996;45(Suppl 1):59-62.
16. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological functions. Endocr Rev 1995;16:3-34.
17. Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997;216:319-57.
18. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low serum insulin-like growth factor-I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002;106:939-44.
19. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: The Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89:114-20.
20. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002;359:1740-5.
21. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
22. Heald A, Selby PL, White A, Gibson JM. Progestogens abrogate estrogen-induced changes in the insulin-growth factor axis. Am J Obstet Gynecol 2000;183:593-600.
23. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestogens used in oral contraceptives. Contraception 1988;38:325-32.
24. Gill MS, Whatmore AJ, Tillman V, White A, Addison GM, Price DA, Clayton PE. Urinary IGF and IGF binding protein-3 in children with disordered growth. Clin Endocrinol (Oxf) 1997;46:483-92.
25. Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4(Suppl 1):11-19.
26. Crosby SR, Anderton CD, Westwood M, Holly JMP, Cwyfan Hughes SC, Gibson JM, Morrison CA, Young RJ, White A. Measurement of insulin-like growth factor-II in human plasma using a specific monoclonal antibody-based two-site immunoradiometric assay. J Endocrinol 1993;137:141-50.
27. Westwood M, Gibson JM, Davies AJ, Young RJ, White A. The phosphorylation pattern of insulin-like growth factor binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrin Metab 1994;79:1735-41.
28. Yates AP, Laing I. Age-related increase in haemoglobin A1c and fasting plasma glucose is accompanied by a decrease in β cell function without change in insulin sensitivity: evidence from a cross-sectional study of hospital personnel. Diabet Med 2002;19:254-8.
29. Lemay A, Dodin S, Cédrin I, T-Lemay L. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate. Clin Endocrinol (Oxf) 1995;42:341-51.
30. Janssen JA, Lamberts SW. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-77.
31. 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 1993;90:10553-7.
32. Rooman RPA, Op de Beeck L, Martin M, Van Doorn J, Mohan S, Du Caju MVL. IGF-I, IGF-II, 'free' IGF-I and IGF binding proteins -2 to -6 during high dose oestrogen treatment in constitutionally tall girls. Eur J Endocrinol 2002;146:823-9.
33. Conover CA, Johnstone EW, Turner RT, Evans GL, John Ballard FJ, Doran PM, Khosla S. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm IGF Res 2002;12:178-83.